UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/525,646	03/24/2005	Takaaki Terahara	7388/84281	8337

20529 7590 08/19/2008

NATH & ASSOCIATES
112 South West Street
Alexandria, VA 22314

EXAMINER	
SASAN, ARADHANA	
ART UNIT	PAPER NUMBER
1615	
MAIL DATE	DELIVERY MODE
08/19/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/525,646	TERAHARA ET AL.	
	Examiner	Art Unit	
	ARADHANA SASAN	1615	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE *3* MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *05 May 2008*.

2a)☒ This action is **FINAL**. 2b)☐ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *1 and 3-7* is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) *1 and 3-7* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date _____.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .
5) ☐ Notice of Informal Patent Application
6) ☐ Other: _____.

DETAILED ACTION

Status of Application

1. The remarks filed on 05/05/08 are acknowledged.

2. Claims 1 and 3-7 are included in the prosecution.

Response to Arguments

Rejection of claim 1 under 35 USC § 102(b)

3. Applicant's arguments, see Pages 1-4, filed 05/05/08, with respect to the rejection of claim 1 under 35 USC § 102(b) as being anticipated by Hoffman (US 5,820,876) have been fully considered and are not persuasive. The rejection of 03/04/08 has been withdrawn.

Rejection of claims 17-18 under 35 USC § 103(a)

4. Applicant's arguments, see Pages 4-9, filed 05/05/08, with respect to the rejection of claims 1 and 3-7 under 35 U.S.C. 103(a) as being unpatentable over Miranda et al. (US 5,656,286), in view of Hoffman (US 5,820,876) have been fully considered but are not persuasive.

Applicant argues that neither the Miranda nor the Hoffman references describe or suggest a single layer containing the combination of components required by the patch formulations of the presently pending claims.

This is not persuasive because Miranda teaches a transdermal drug delivery system "wherein a blend of at least two polymers … permits increased loading of a drug and adjusts the solubility of a drug in the blend and thereby modulates the delivery of the drug from the system and through the dermis" (Col. 2, lines 51-57). Since Miranda

teaches the drug in the polymeric adhesive system (Col. 1, lines 24-34), one with ordinary skill in the art would know that the drug is in a single layer with the blend of polymers. Figure 1 of Miranda shows a monolithic transdermal drug delivery device. The single drug comprising polymer layer is further recited in claim 13 of Miranda.

Applicant argues that the Hoffman reference teaches away by disclosing patch formulations where the layer structure and the combination of components in the layer(s) are different from those recited in the presently pending claims.

This is not persuasive because one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.,* 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). Hoffman cures the deficiency of Miranda and is used as a supporting reference that provides the teaching of self-crosslinking acrylate copolymer of 2-ethyl-hexyl acrylate and vinyl acetate in a transdermal therapeutic system (Col. 7, lines 1-8).

Therefore, the rejection of 03/04/08 is maintained.

Provisional Rejection of claims 1 and 4-6 under nonstatutory obviousness-type double patenting

5. Applicant's arguments, see Pages 10-11, filed 05/05/08, with respect to the provisional rejection of claims 1 and 4-6 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-11 of copending Application No. 10/526,065 ('065 hereinafter) have been fully considered but are not persuasive.

Applicant argues that claims 1-11 of '065 do not recite the specific combination of components in the adhesive layer that are required by pending claims 1 and 4-6 of the instant application and that accordingly, present claims 1 and 4-6 are patentably distinct from the claims 1-11 of co-pending Application No. 10/526,065.

This is not persuasive because the difference between instant claims and those of '065 is that claims of '065 include the limitation of the weight ratio of the content of the acrylic polymer to the content of the rubber polymer and the weight ratio of the content of the acrylic polymer and the rubber polymer to the content of the basic nitrogen-including polymer. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the ratio of the content of the acrylic polymer to the content of the rubber polymer and the weight ratio of the content of the acrylic polymer and the rubber polymer to the content of the basic nitrogen-including polymer during the process of routine experimentation in order to achieve optimal skin absorption of the drug. The instant claims are obvious over the claims of '065 and thus they are not patentably distinct over each other.

Therefore, the rejection of 03/04/08 is maintained.

MAINTAINED REJECTIONS:

The following is a list of maintained rejections:

Claim Rejections - 35 USC § 103

6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

> (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the

> invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

7. Claims 1 and 3-7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Miranda et al. (US 5,656,286), in view of Hoffman (US 5,820,876).

Miranda teaches "a transdermal drug delivery composition wherein a blend of polymers is utilized to affect the rate of drug delivery from the composition. More specifically, a plurality of polymers … having differing solubility parameters, preferably immiscible with each other, adjusts the solubility of the drug in a polymeric adhesive system formed by the blend, affects the maximum concentration of the drug in the system, and modulates the delivery of the drug from the composition and through the dermis" (Col. 1, lines 24-34). Styrene-isoprene-styrene block copolymers are disclosed as rubber-based pressure-sensitive adhesives useful in the transdermal composition (Col. 11, lines 20-24). Acrylate polymers useful in the composition are "polymers of one or more monomers of acrylic acids and other copolymerizable monomers … the acrylate polymer is composed of at least 50% by weight of an acrylate or alkyl acrylate monomer, from 0 to 20% of a functional monomer copolymerizable with the acrylate, and from 0 to 40% of other monomers … Acrylate monomers which can be used include … butyl methacrylate, … 2-ethylhexyl acrylate, …" (Col. 10, lines 46-62). Functional monomers that are copolymerizable with the alkyl acrylates include methacrylic acid, dimethylaminoethyl methacrylate (Col. 10, line 66 to Col. 11, line 4). The antiparkinsonian drug, pergolide, is disclosed as a drug that can be administered by the transdermal drug delivery system (Col. 23, lines 45-49).

Miranda does not expressly teach 2-ethylhexyl acrylate-vinyl acetate copolymer.

Hoffman teaches a transdermal therapeutic system for supplying active substances to the skin (Abstract). The active substance reservoir matrix can be a rubber material such as styrene-isoprene-styrene block copolymer (Col. 4, lines 2-6). Adhesive materials including a self-crosslinking acrylate copolymer, e.g. of 2-ethyl-hexyl acrylate, vinyl acetate and an acrylic resin of dimethylaminoethylmethacrylate and neutral methacrylate (EUDRAGIT E 100 from RÖHM) are disclosed (Col. 7, lines 1-8).

It would have been obvious to one of ordinary skill in the art at the time the invention was made to make a transdermal drug delivery composition with styrene-isoprene-styrene block copolymers as rubber-based pressure-sensitive adhesives and butyl methacrylate that is copolymerizable with methacrylic acid and dimethylaminoethyl methacrylate as suggested by Miranda, combine it with the transdermal composition with styrene-isoprene-styrene block copolymer, copolymer of 2-ethyl-hexyl acrylate and vinyl acetate, and an acrylic resin of dimethylaminoethylmethacrylate and neutral methacrylate (EUDRAGIT E 100 from RÖHM), as suggested by Hoffman, and produce the instant invention.

One of ordinary skill in the art would have been motivated to do this because Hoffman teaches that the copolymer of 2-ethyl-hexyl acrylate and vinyl acetate is a self-crosslinking acrylate copolymer (Col. 7, lines 1-3).

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was *prima facie* obvious to one of

ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

Regarding instant claim 1, the limitation of the styrene-isoprene-styrene block copolymer would have been obvious over the styrene-isoprene-styrene block copolymers taught by Miranda (Col. 11, lines 20-24). The limitation of 2-ethylhexyl acrylate-vinyl acetate copolymer would have been obvious over the copolymer of 2-ethyl-hexyl acrylate, vinyl acetate taught by Hoffman (Col. 7, lines 1-3). The limitation of the basic nitrogen including polymer would have been obvious over the acrylic resin of dimethylaminoethylmethacrylate and neutral methacrylate (EUDRAGIT E 100 from RÖHM) taught by Hoffman (Col. 7, lines 1-8).

Regarding instant claims 3-4, the limitation of the drug would have been obvious over the pergolide taught by Miranda (Col. 11, lines 20-24)

Regarding instant claim 5, the limitation of the adhesive layer further comprising an organic acid would have been obvious over the enhancers including ascorbic acid taught by Miranda (Col. 33, lines 16-34).

Regarding instant claim 6, the limitation of the adhesive layer further comprising an alicyclic saturated hydrocarbon-based tackifier would have been obvious over the plasticizer or tackifying agents including aromatic hydrocarbons taught by Miranda (Col. 33, lines 37-45).

Regarding instant claim 7, the limitation of the weight ratio of the content of the styrene-isoprene-styrene block copolymer to the content of the 2-ethyl-hexyl acrylate

vinyl acetate copolymer would have been obvious over the teaching by Miranda that "by varying the amount of each type of monomer added, the cohesive properties of the resulting acrylate polymer can be changed as is known in the art" (Col. 10, lines 51-54). Therefore, one with ordinary skill in the art would modify the ratio of the styrene-isoprene-styrene block copolymer to the content of the 2-ethyl-hexyl acrylate vinyl acetate copolymer during the process of routine experimentation, and the recited ratio would have been an obvious variant unless there is evidence of criticality or unexpected results.

Double Patenting

8. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

9. Claims 1 and 4-6 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-11 of

copending Application No. 10/526,065 ('065 hereinafter). Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims are drawn to a patch comprising a backing layer and an adhesive layer that is compounded with a drug and an adhesive base agent. The adhesive base agent comprises styrene-isoprene-styrene block copolymer, 2-ethylhexyl acrylate-vinyl acetate copolymer and a basic nitrogen-including polymer, which is selected from methyl acrylate-butyl methacrylate-dimethylaminoethyl methacrylate and polyvinyl acetal diethylamino acetate. The drug is selected from a group containing pergolide. The adhesive layer also comprises an organic acid and an alicyclic saturated hydrocarbon-based tackifier.

Claims 1-11 of '065 are also drawn to a patch comprising a backing layer and an adhesive layer compounded with an adhesive base agent and pergolide. The adhesive base agent comprises an acrylic polymer, a basic nitrogen-including polymer selected from methyl methacrylate-butyl methacrylate-dimethylaminoethyl methacrylate terpolymer and polyvinyl acetal diethylamino acetate. The adhesive layer also comprises an alicyclic saturated hydrocarbon resin-based tackifier. 2-ethylhexyl acrylate-vinyl acetate copolymer is claimed as an acrylic polymer and styrene-isoprene-styrene block copolymer is claimed as the rubber polymer. The adhesive layer also contains an organic acid (acetic acid and/or a pharmaceutically acceptable salt). The difference between the instant claims and those of '065 is that claims of '065 include the limitation of the weight ratio of the content of the acrylic polymer to the content of the rubber polymer and the weight ratio of the content of the acrylic polymer

and the rubber polymer to the content of the basic nitrogen-including polymer. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the ratio of the content of the acrylic polymer to the content of the rubber polymer and the weight ratio of the content of the acrylic polymer and the rubber polymer to the content of the basic nitrogen-including polymer during the process of routine experimentation in order to achieve optimal skin absorption of the drug.

The instant claims are obvious over the claims of '065 and thus they are not patentably distinct over each other.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Conclusion

10. No claims are allowed.

11. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Aradhana Sasan whose telephone number is (571) 272-9022. The examiner can normally be reached Monday to Thursday from 6:30 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, can be reached at 571-272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Aradhana Sasan/
Examiner, Art Unit 1615

/MP WOODWARD/
Supervisory Patent Examiner, Art Unit 1615